Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation
BeiGene, Hengrui Head Local R&D Push
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
